Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.53 |
| ▸ | PANK3 | Q9H999 | 8/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454291 | 0.85 | PANK3 (0.49) | DPP4DPP8DPP9PANK3HRH3 | |
| SCHEMBL16627291 | 0.84 | HRH3 (0.61) | DPP4DPP8DPP9PANK3HRH3 | |
| SCHEMBL3453143 | 0.83 | DPP4 (0.53) | DPP4PANK3HRH3CHRM4 | |
| SCHEMBL26124147 | 0.83 | CHRM1 (0.52) | DPP4DPP8DPP9PANK3CHRM4 | |
| SCHEMBL3460040 | 0.81 | HRH3 (0.59) | HRH3JAK2JAK3PARP1 | |
| SCHEMBL3453713 | 0.81 | HRH3 (0.54) | HRH3 | |
| SCHEMBL2825721 | 0.79 | HRH3 (0.55) | DPP4DPP8DPP9PANK3HRH3 | |
| SCHEMBL19748857 | 0.78 | HRH3 (0.54) | DPP4DPP8DPP9PANK3HRH3 | |
| SCHEMBL19748850 | 0.78 | PANK3 (0.61) | DPP4DPP8DPP9PANK3CHRM4 | |
| SCHEMBL326846 | 0.75 | CHRM4 (0.55) | DPP4DPP8DPP9PANK3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820817-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100105693-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105693-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | DPP4 1539/4885DPP8 2022/4885DPP9 2536/4885 |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | ACHE, CHRM5, CHRM3 | DPP4 877/4885DPP8 1150/4885DPP9 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.